<DOC>
	<DOCNO>NCT01236638</DOCNO>
	<brief_summary>This extension protocol core study CCL09101 allow patient tolerated drug derive clinical benefit , continue receive treatment beyond 9 cycle core protocol . Long term safety efficacy CYT387 evaluate .</brief_summary>
	<brief_title>Extension Study Evaluating Long Term Safety Efficacy Study CYT387 Primary Myelofibrosis ( PMF ) Post-polycythemia Vera ( PV ) Post-essential Thrombocythemia ( ET )</brief_title>
	<detailed_description>The myeloproliferative neoplasm ( MPN ) , notably polycythemia vera ( PV ) , essential thrombocythemia ( ET ) , primary myelofibrosis ( PMF ) diverse inter-related suite clonal disorder pluripotent hematopoietic stem cell ( Tefferi et al. , 2008 ) . The MPN share range biological , pathological , clinical feature include relative overproduction one cell myeloid origin , growth factor independent colony formation vitro , marrow hypercellularity , extramedullary hematopoiesis , spleno- hepatomegaly , thrombotic and/or hemorrhagic diatheses ( Tefferi et al. , 2005 ) . This multi centre , open-label , extension study core study ( CCL09101 ) . The primary aim study determine long term safety tolerability orally-administered CYT387 administer capsule dose , 28-day treatment cycle . Following completion core study ( CCL09101 ) , patient tolerate drug derive clinical benefit continue treat CYT387 administer orally . Subjects evaluate every three month 24 cycle CYT387 treatment . Subjects return follow-up visit 30 day completion last dose study drug .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Patients must complete least 9 cycle treatment core study ' A Phase I/II , OpenLabel , DoseEscalation Study Evaluating Safety , Tolerability , Pharmacokinetics Pharmacodynamics OrallyAdministered CYT387 Primary Myelofibrosis PostPolycythemia Vera PostEssential Thrombocythemia Myelofibrosis ( CCL09101 ) ' achieve stable disease ( SD ) , clinical improvement ( CI ) , partial remission ( PR ) complete remission ( CR ) use International Working Group consensus criterion treatment response myelofibrosis myeloid metaplasia ( IWGMRT ; Tefferi et al. , 2006 ) Must able provide inform consent willing sign inform consent form . Must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Must evidence acceptable organ function within 7 day initiate study drug evidence follow : SGOT ( AST ) SGPT ( ALT ) &lt; = 2.5 x upper limit normal ( ULN ) ( &lt; = 5 x ULN investigator 's opinion elevation due extramedullary hematopoiesis ) Bilirubin &lt; = 2.0 x ULN direct bilirubin &lt; 1.0 Serum creatinine &lt; = 2.5 x ULN Absolute neutrophil count &gt; = 500/µL Platelet count &gt; = 20,000/µL Females childbearing potential must negative pregnancy test within 4 day enter extension protocol . A delay 4 week since last preceding dose CYT387 CCL09101 core study . Any chemotherapy ( e.g. , hydroxyurea ) , immunomodulatory drug therapy ( e.g. , thalidomide ) , immunosuppressive therapy , corticosteroid &gt; 10 mg/day prednisone equivalent , growth factor treatment ( e.g. , erythropoietin ) within 14 day prior initiation study drug . Incomplete recovery major surgery within four week study entry . Radiation therapy within four week study entry . Women childbearing potential , unless surgically sterile least 3 month ( i.e. , hysterectomy ) , OR postmenopausal least 12 month ( FSH &gt; 30 U/mL ) , OR unless agree take appropriate precaution avoid pregnancy ( least 99 % certainty ) screen end study . Permitted method prevent pregnancy must communicate study subject understand confirm . Men partner woman childbearing potential , unless agree take appropriate precaution avoid pregnancy ( least 99 % certainty ) screen end study . Permitted method prevent pregnancy must communicate study subject understand confirm . Females pregnant currently breastfeed . Known positive status HIV . Clinically active hepatitis B C. Diagnosis another malignancy unless free disease least three year follow therapy curative intent . Patients earlystage basal cell squamous cell skin cancer , cervical intraepithelial neoplasia , cervical carcinoma situ superficial bladder cancer may eligible participate Investigator 's discretion . Any acute active infection . Cardiac dysrhythmias require treatment , prolongation QTc ( Fridericia ) interval &gt; 450 msec male &gt; 470 msec female prestudy screen , unless attributable preexist bundle branch block . Presence &gt; = Grade 2 peripheral neuropathy . Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , uncontrolled unstable angina , myocardial infarction , cerebrovascular accident , pulmonary embolism within 3 month prior initiation study drug . Uncontrolled inter current illness concurrent condition , Investigator 's opinion , would jeopardize safety patient compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>Post-Polycythemia Vera</keyword>
	<keyword>Post-Essential Thrombocythemia</keyword>
	<keyword>CYT387</keyword>
</DOC>